Haemonetics Corporation
Financials
Valuation Metrics
Haemonetics Corporation's Market Cap is $5.46B. At end of 2025 it was $3.75B. Ranked #1275 of 3,118 in US market (top 41%), #850 of 1,644 on NYSE (top 52%), #83 of 203 in Health Care Equipment & Services (top 41%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $5.46B | US#1,275/3,118 Sec#83/203 |
| Revenue | $1.35B | US#1,687/3,118 Sec#106/203 |
| Net Income | $96M | US#1,632/3,118 Sec#85/203 |
| Total Assets | $2.37B | US#1,967/3,118 Sec#95/203 |
| Net Assets | $837M | US#1,876/3,118 Sec#98/203 |
| Employees | 3,023 | US#1,467/3,118 Sec#103/203 |
| Value | ||
| P/E | 56.73x | US#1,951/3,118 Sec#103/203 |
| P/B | 6.53x | US#2,401/3,118 Sec#149/203 |
| P/S | 4.04x | US#2,090/3,118 Sec#138/203 |
| EV/EBITDA | 24.55x | US#2,085/3,118 Sec#101/203 |
| FCF Yield | 5.33% | US#1,301/3,118 Sec#58/203 |
| Profitability | ||
| ROE | 11.50% | US#1,197/3,118 Sec#59/203 |
| ROA | 4.07% | US#1,208/3,118 Sec#80/203 |
| Op. Margin | 18.18% | US#990/3,118 Sec#31/203 |
| Revenue Growth | 0.44% | US#2,176/3,118 Sec#164/203 |
| Earnings Growth | -41.05% | US#1,659/3,118 Sec#90/203 |
| Financial Health | ||
| Debt Ratio | 182.57% | US#1,693/3,118 Sec#145/203 |
| Total Debt | $1.17B | US#1,440/3,118 Sec#78/203 |
| FCF | $291M | US#1,181/3,118 Sec#70/203 |
| Cash | $223M | US#1,648/3,118 Sec#97/203 |
| Current Ratio | 3.08x | US#749/3,118 Sec#75/203 |
| Net Debt/EBITDA | 3.64x | US#1,779/3,118 Sec#117/203 |
| Performance | ||
| 1Y Return | 140.36% | US#66/3,118 Sec#11/203 |
| 1M Return | 14.83% | US#519/3,118 Sec#40/203 |
| From 52W High | -2.88% | US#274/3,118 Sec#19/203 |
| 1Y MDD | -40.06% | US#1,931/3,118 Sec#121/203 |
| Trading | ||
| Volume | 486,992 shares | US#2,386/3,118 Sec#170/203 |
| Trading Value | $59M | US#1,501/3,118 Sec#105/203 |
| Per Share | ||
| EPS | $2.12 | US#1,299/3,118 Sec#68/203 |
| BPS | $18.42 | US#1,317/3,118 Sec#75/203 |
Company Info
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.